Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

First-line immunotherapy of metastatic renal cell carcinoma: an updated network meta-analysis including triplet therapy

T. Yanagisawa, T. Kawada, K. Bekku, E. Laukhtina, P. Rajwa, M. von Deimling, M. Chlosta, F. Quhal, B. Pradere, PI. Karakiewicz, K. Mori, T. Kimura, SF. Shariat, M. Schmidinger

. 2024 ; 134 (3) : 323-336. [pub] 20240424

Jazyk angličtina Země Anglie, Velká Británie

Typ dokumentu časopisecké články, metaanalýza, systematický přehled

Perzistentní odkaz   https://www.medvik.cz/link/bmc24019191

OBJECTIVE: To compare the differential efficacy of first-line immune checkpoint inhibitor (ICI)-based combined therapies among patients with intermediate- and poor-risk metastatic renal cell carcinoma (mRCC), as recently, the efficacy of triplet therapy comprising nivolumab plus ipilimumab plus cabozantinib has been published. PATIENTS AND METHODS: Three databases were searched in December 2022 for randomised controlled trials (RCTs) analysing oncological outcomes in patients with mRCC treated with first-line ICI-based combined therapies. We performed network meta-analysis (NMA) to compare the outcomes, including progression-free survival (PFS) and objective response rates (ORRs), in patients with intermediate- and poor-risk mRCC; we also assessed treatment-related adverse events. RESULTS: Overall, seven RCTs were included in the meta-analyses and NMAs. Treatment ranking analysis revealed that pembrolizumab + lenvatinib (99%) had the highest likelihood of improved PFS, followed by nivolumab + cabozantinib (79%), and nivolumab + ipilimumab + cabozantinib (77%). Notably, compared to nivolumab + cabozantinib, adding ipilimumab to nivolumab + cabozantinib did not improve PFS (hazard ratio 1.02, 95% confidence interval 0.72-1.43). Regarding ORRs, treatment ranking analysis also revealed that pembrolizumab + lenvatinib had the highest likelihood of providing better ORRs (99.7%). The likelihoods of improved PFS and ORRs of pembrolizumab + lenvatinib were true in both International Metastatic RCC Database Consortium (IMDC) risk groups. CONCLUSIONS: Our analyses confirmed the robust efficacy of pembrolizumab + lenvatinib as first-line treatment for patients with intermediate or poor IMDC risk mRCC. Triplet therapy did not result in superior efficacy. Considering both toxicity and the lack of mature overall survival data, triplet therapy should only be considered in selected patients.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc24019191
003      
CZ-PrNML
005      
20241024111647.0
007      
ta
008      
241015s2024 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1111/bju.16336 $2 doi
035    __
$a (PubMed)38659099
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Yanagisawa, Takafumi $u Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria $u Department of Urology, The Jikei University School of Medicine, Tokyo, Japan $1 https://orcid.org/0000000274100712
245    10
$a First-line immunotherapy of metastatic renal cell carcinoma: an updated network meta-analysis including triplet therapy / $c T. Yanagisawa, T. Kawada, K. Bekku, E. Laukhtina, P. Rajwa, M. von Deimling, M. Chlosta, F. Quhal, B. Pradere, PI. Karakiewicz, K. Mori, T. Kimura, SF. Shariat, M. Schmidinger
520    9_
$a OBJECTIVE: To compare the differential efficacy of first-line immune checkpoint inhibitor (ICI)-based combined therapies among patients with intermediate- and poor-risk metastatic renal cell carcinoma (mRCC), as recently, the efficacy of triplet therapy comprising nivolumab plus ipilimumab plus cabozantinib has been published. PATIENTS AND METHODS: Three databases were searched in December 2022 for randomised controlled trials (RCTs) analysing oncological outcomes in patients with mRCC treated with first-line ICI-based combined therapies. We performed network meta-analysis (NMA) to compare the outcomes, including progression-free survival (PFS) and objective response rates (ORRs), in patients with intermediate- and poor-risk mRCC; we also assessed treatment-related adverse events. RESULTS: Overall, seven RCTs were included in the meta-analyses and NMAs. Treatment ranking analysis revealed that pembrolizumab + lenvatinib (99%) had the highest likelihood of improved PFS, followed by nivolumab + cabozantinib (79%), and nivolumab + ipilimumab + cabozantinib (77%). Notably, compared to nivolumab + cabozantinib, adding ipilimumab to nivolumab + cabozantinib did not improve PFS (hazard ratio 1.02, 95% confidence interval 0.72-1.43). Regarding ORRs, treatment ranking analysis also revealed that pembrolizumab + lenvatinib had the highest likelihood of providing better ORRs (99.7%). The likelihoods of improved PFS and ORRs of pembrolizumab + lenvatinib were true in both International Metastatic RCC Database Consortium (IMDC) risk groups. CONCLUSIONS: Our analyses confirmed the robust efficacy of pembrolizumab + lenvatinib as first-line treatment for patients with intermediate or poor IMDC risk mRCC. Triplet therapy did not result in superior efficacy. Considering both toxicity and the lack of mature overall survival data, triplet therapy should only be considered in selected patients.
650    _2
$a lidé $7 D006801
650    12
$a anilidy $x terapeutické užití $7 D000813
650    _2
$a humanizované monoklonální protilátky $x terapeutické užití $7 D061067
650    12
$a protokoly protinádorové kombinované chemoterapie $x terapeutické užití $7 D000971
650    12
$a karcinom z renálních buněk $x farmakoterapie $x mortalita $x sekundární $7 D002292
650    12
$a inhibitory kontrolních bodů $x terapeutické užití $7 D000082082
650    _2
$a imunoterapie $x metody $7 D007167
650    _2
$a ipilimumab $x terapeutické užití $7 D000074324
650    12
$a nádory ledvin $x farmakoterapie $x mortalita $x patologie $7 D007680
650    _2
$a síťová metaanalýza $7 D000071076
650    _2
$a nivolumab $x terapeutické užití $7 D000077594
650    _2
$a fenylmočovinové sloučeniny $x terapeutické užití $7 D010671
650    _2
$a doba přežití bez progrese choroby $7 D000077982
650    _2
$a pyridiny $x terapeutické užití $7 D011725
650    _2
$a chinoliny $x terapeutické užití $7 D011804
650    _2
$a randomizované kontrolované studie jako téma $7 D016032
655    _2
$a časopisecké články $7 D016428
655    _2
$a metaanalýza $7 D017418
655    _2
$a systematický přehled $7 D000078182
700    1_
$a Kawada, Tatsushi $u Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria $u Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan $1 https://orcid.org/0000000283699712
700    1_
$a Bekku, Kensuke $u Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria $u Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan $1 https://orcid.org/0000000300021592
700    1_
$a Laukhtina, Ekaterina $u Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria $1 https://orcid.org/0000000289530272
700    1_
$a Rajwa, Pawel $u Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria $u Department of Urology, Medical University of Silesia, Zabrze, Poland $1 https://orcid.org/0000000340736584
700    1_
$a von Deimling, Markus $u Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria $u Department of Urology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
700    1_
$a Chlosta, Marcin $u Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria $u Clinic of Urology and Urological Oncology, Jagiellonian University, Krakow, Poland
700    1_
$a Quhal, Fahad $u Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria $u Department of Urology, King Fahad Specialist Hospital, Dammam, Saudi Arabia
700    1_
$a Pradere, Benjamin $u Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria $u Department of Urology, La Croix Du Sud Hospital, Quint Fonsegrives, France
700    1_
$a Karakiewicz, Pierre I $u Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montreal Health Center, Montreal, Québec, Canada
700    1_
$a Mori, Keiichiro $u Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria $u Department of Urology, The Jikei University School of Medicine, Tokyo, Japan $1 https://orcid.org/0000000261476569
700    1_
$a Kimura, Takahiro $u Department of Urology, The Jikei University School of Medicine, Tokyo, Japan
700    1_
$a Shariat, Shahrokh F $u Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria $u Karl Landsteiner Institute of Urology and Andrology, Vienna, Austria $u Division of Urology, Department of Special Surgery, The University of Jordan, Amman, Jordan $u Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX, USA $u Department of Urology, Weill Cornell Medical College, New York, NY, USA $u Department of Urology, Second Faculty of Medicine, Charles University, Prague, Czech Republic
700    1_
$a Schmidinger, Manuela $u Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria
773    0_
$w MED00011371 $t BJU international $x 1464-410X $g Roč. 134, č. 3 (2024), s. 323-336
856    41
$u https://pubmed.ncbi.nlm.nih.gov/38659099 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20241015 $b ABA008
991    __
$a 20241024111640 $b ABA008
999    __
$a ok $b bmc $g 2201809 $s 1231164
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2024 $b 134 $c 3 $d 323-336 $e 20240424 $i 1464-410X $m BJU international $n BJU Int $x MED00011371
LZP    __
$a Pubmed-20241015

Najít záznam

Citační ukazatele

Nahrávání dat ...

Možnosti archivace

Nahrávání dat ...